| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_68c213ba9952360f439567152e047b18 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-451
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-454
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D211-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04 |
| filingDate |
2018-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2636f162fbd5ac2b0d619d4c613b4c15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ff0be5db31ce557c852308683d0c5bc |
| publicationDate |
2018-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2018155332-A1 |
| titleOfInvention |
Small molecule based antibody-recruiting compounds for cancer treatment |
| abstract |
The present invention relates to chimeric (including bifunctional) compounds, compositions comprising those compounds and methods of treating cancer in a patient or subject, especially including metastatic cancer where cancer cells exhibit overexpression (heightened expression) of cell surface urokinase-type plasminogen activator receptor (urokinase receptor) compared to normal (non-cancerous) cells. The compounds bind to the urokinase-type plasminogen activator receptor (uPAR) on the surface of a cancer cell, including a metastatic cancer cell, and consequently recruit native antibodies of the patient or subject where the antibodies can selectively degrade and/or deactivate targeted cancer cells through antibody-dependent cellular phagocytosis and antibody-dependent cellular cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) against a large number and variety of cancers, thus providing cancer cell death and an inhibition of growth, elaboration and/or metastasis of the cancer, including remission and cure of the patient's cancer. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020132588-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10780084-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021072246-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109925509-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113454124-A |
| priorityDate |
2015-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |